Clinical Trial

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-11.
Trial Details
NCT Number NCT07472153
Lead Sponsor N.N. Alexandrov National Cancer Centre
Conditions Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer
Enrollment 120 participants
Start Date 2025-07-01
Primary Completion 2030-06-30 (estimated)
Study Completion 2033-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28